Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
1762
mi
from 91732
Nashville, TN
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
1224
mi
from 91732
Dallas, TX
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Charles A. Sammons Cancer Center at Baylor University Medical Center
1224
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
962
mi
from 91732
Seattle, WA
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
962
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Decision Aid for Therapeutic Options In Sickle Cell Disease
Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease
Status: Enrolling
Updated:  12/31/1969
Emory University
1919
mi
from 91732
Atlanta, GA
Decision Aid for Therapeutic Options In Sickle Cell Disease
Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease
Status: Enrolling
Updated: 12/31/1969
Emory University
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2277
mi
from 91732
Bethesda, MD
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2245
mi
from 91732
Rochester, NY
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2245
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from 91732
Springfield, OR
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from 91732
Springfield, OR
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
874
mi
from 91732
Yakima, WA
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
874
mi
from 91732
Yakima, WA
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
26
mi
from 91732
Santa Monica, CA
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
26
mi
from 91732
Santa Monica, CA
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
827
mi
from 91732
Portland, OR
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
CBCC Global Research Inc. at Comprehensive Blood and Cancer Center
106
mi
from 91732
Bakersfield, CA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
CBCC Global Research Inc. at Comprehensive Blood and Cancer Center
106
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Providence Saint-Joseph Medical Center
19
mi
from 91732
Burbank, CA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Providence Saint-Joseph Medical Center
19
mi
from 91732
Burbank, CA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Compassionate Care Research Group, Inc.
25
mi
from 91732
Fountain Valley, CA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Compassionate Care Research Group, Inc.
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Los Angeles Hematology/Oncology Medical Group
14
mi
from 91732
Los Angeles, CA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Los Angeles Hematology/Oncology Medical Group
14
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Colorado
820
mi
from 91732
Aurora, CO
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Colorado
820
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
2203
mi
from 91732
Fort Myers, FL
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
2203
mi
from 91732
Fort Myers, FL
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2134
mi
from 91732
Tampa, FL
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
2304
mi
from 91732
West Palm Beach, FL
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
2304
mi
from 91732
West Palm Beach, FL
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Dana Farber/Partners Cancer Care
2578
mi
from 91732
Boston, MA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Dana Farber/Partners Cancer Care
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
John Theurer Cancer Center at the Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Alliance
2435
mi
from 91732
New York, NY
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Alliance
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering
2432
mi
from 91732
New York, NY
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Morton Coleman, MD
2432
mi
from 91732
New York, NY
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Morton Coleman, MD
2432
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
2434
mi
from 91732
New York, NY
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
2503
mi
from 91732
Stony Brook, NY
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
2503
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Durham Veterans Affairs Medical Center
2202
mi
from 91732
Durham, NC
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Durham Veterans Affairs Medical Center
2202
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
1887
mi
from 91732
Cincinnati, OH
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
1887
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Bend Memorial Clinic
714
mi
from 91732
Bend, OR
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Bend Memorial Clinic
714
mi
from 91732
Bend, OR
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Hollings Cancer Center
2184
mi
from 91732
Charleston, SC
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Hollings Cancer Center
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Greenville Health System
2018
mi
from 91732
Greenville, SC
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Greenville Health System
2018
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Saint Francis Hospital Cancer Center
2019
mi
from 91732
Greenville, SC
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Saint Francis Hospital Cancer Center
2019
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Avera Cancer Institute
1314
mi
from 91732
Sioux Falls, SD
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Avera Cancer Institute
1314
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The West Clinic, PC
1597
mi
from 91732
Memphis, TN
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The West Clinic, PC
1597
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute
1763
mi
from 91732
Nashville, TN
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
1762
mi
from 91732
Nashville, TN
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
572
mi
from 91732
Salt Lake City, UT
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
961
mi
from 91732
Seattle, WA
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care, Aurora Cancer Care
1729
mi
from 91732
Milwaukee, WI
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care, Aurora Cancer Care
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Lombardi Cancer Center, Pediatric Hematology Oncology
2279
mi
from 91732
Washington,
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Lombardi Cancer Center, Pediatric Hematology Oncology
2279
mi
from 91732
Washington,
Click here to add this to my saved trials
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
2129
mi
from 91732
Winston-Salem, NC
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
2129
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
573
mi
from 91732
Salt Lake City, UT
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials